

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00) #13

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/413,758
		Filing Date	October 7, 1999
		First Named Inventor	Manolagas, et al.
		Group Art Unit	1633 1632
		Examiner Name	
		Attorney Docket Number	06572.105003 (ANA1002)
Sheet	1		

RECEIVED
FEB 08 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AMB	AA	4,588,716		DeLuca et al.	05-13-1986	
	AB	4,833,125		Neer et. al.	05-23-1989	
	AC	5,118,667		Adams et. al.	06-02-1992	
	AD	5,164,368		Recker et. al.	11-17-1992	
	AE	5,510,370		Hock et. al.	04-23-1996	
AMB	AF	5,565,444		Mizushi, Y. et. al.	10-15-1996	

Examiner Signature	Anne-Marie Baker	Date Considered	3/18/02
-----------------------	------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/413,758
		Filing Date	October 7, 1999
		First Named Inventor	Manolagas, et al.
		Class Art Unit	1633 1632
		Examiner Name	
		Examiner Docket Number	06572.105003 (ANA1002)
Sheet	2	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AmB	BA	BELLIDO et. al. "PTH Prevents Glucocorticoid Apoptosis of Osteoblasts and Osteocytes In Vitro: Direct Interference with a private Death Pathway Upstream of Caspase-3." Abstract. <i>Bone</i> . 5: S518: F458 (1998).	
	BB	DEMPSTER, D.W., "Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of Osteoporosis," <i>Journal of Bone and Mineral Research</i> . 12(8):1152-1154 (1997).	
	BC	FERRETTI, J.L. et al. "Perspectives on Osteoporosis Research: Its Focus and Some Insights rom a New Paradigm." <i>Calcif. Tissue Int</i> . 57:399 (1995).	
	BD	FORREST, S.M. et al. "Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin." <i>Calcif. Tissue Int</i> . 37:51-56 (1985).	
	BE	GOHEL, A. et al., "Glucocorticoids Induce Apoptosis in Osteoblasts by the Regulation of Bcl-2, BAX and other cell cycle factor," <i>Journal of Bone and Mineral Research</i> . Abstract F234:S284 (1997).	
	BF	HUGHES, D.E. et al. "Apoptosis in Bone Physiology and Disease." MP. <i>Molecular Pathology</i> , BMJ Publishing Group, Vol. 50: 132-137 (1997) London, GB.	
	BG	HUGHES, D.E. et al., "Bisphosphonates Promote Apoptosis in Murine Osteoclasts In Vitro and In Vivo," <i>Journal of Bone and Mineral Research</i> . Vol. 10(10):1478-1487 (October 1995).	
	BH	IIDA-KLEIN, A. et al., "Effects of Calcitonin on 3', 5'-Cyclic Adenosine Monophosphate and Calcium Second Messenger Generation and Osteoblast Function in UMR 106-06 Osteoblast-Like Cells," <i>Endocrinology</i> . 130(1):381-388 (1992).	
	BI	JILKA et al. "Dexamethasone Promotes Apoptosis of Osteoblast Progenitors in Murine Bone Marrow Cultures: Antagonism by IL-6 Type Cytokines" <i>Journal of Bone and Mineral Research</i> (1997) 12(Supp): S455, abstract number S411.	
	BJ	JILKA, R.L. et al., "Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone," <i>Journal of Clinical Investigation</i> . Vol. 104(4):439-446 (August 1999).	
AmB	BK ²	JILKA, R.L. et al., "Osteoblast Programmed Cell Death (Apoptosis): Modulation by Growth Factors and Cytokines," <i>Journal of Bone and Mineral Research</i> . Vol. 13(5):793-802 (1998).	

Examiner Signature	Anne-Marie Baker	Date Considered	3/18/02
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/413,758
		Filing Date	Oct ber 7, 1999
		First Named Inventor	Manolagas, et al.
		Group Art Unit	1633- 1632
		Examiner Name	
		Attorney Docket Number	06572.105003 (ANA1002)
Sheet	3	of	

RECEIVED
FEB 08 2002
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
amb	CA	KAMEDA, T. et al., "Estrogen Inhibits Bone Resorption by Directly Inducing Apoptosis of the Bone-resorbing Osteoclasts," <i>The Journal of Experimental Medicine</i> . Vol. 186(3):489-495 (August 4, 1997).	
	CB	LEAFFER, D. et al., "Modulation of Osteogenic Cell Ultrastructure by RS-23581, an Analog of Human Parathyroid Hormone (PTH)-Related Peptide-(1-34), and Bovine PTH-(1-34)," <i>Endocrinology</i> , Vol. 136(8): 3624-3631 (August 1995).	
	CD	LIAN, J.B. et. al. "Species-Specific Glucocorticoid and 1,25 Dihydroxyvitamin D Responsiveness in Mouse MC3T3-E1 Osteoblasts: Dexamethadone Inhibits Osteoblast Differentiation and Vitamin D Downregulates Osteocalcin Gene Expression," <i>Endocrinology</i> , Vol. 138(5): 2117-2127 (1997).	
	CE	MANOLAGAS et al. "Bone Marrow, Cytokines, and Bone Remodeling." <i>New England Journal of Medicine</i> . Vol. 332: 305-311 (February 2, 1995).	
	CF	MANOLAGAS et al. "New Developments in the pathogenesis and treatment of steroid-induced osteoporosis." <i>Journal of Bone and Mineral Research</i> . Vol. 14(7):1061-1066 (1999).	
	CG	MANOLAGAS, S.C. et al., "Opposite Effects of Estrogen on the Life Span of Osteoblasts/Osteocytes Versus Osteoclasts In Vivo and In Vitro: An Explanation of the Imbalance between Formation and Resorption in Estrogen Deficiency," <i>Journal of Bone and Mineral Research</i> 14:S169 (1999) (Abstract).	
	CH	MAROTTI, G. et al., "Structure-function relationships in the osteocyte," <i>Italian Journal of Mineral & Electrolyte Metabolism</i> . Vol. 4(2):93-106 (1990).	
	CI	NISHIKAWA, M. et al., "Bisphosphonates Act on Osteoblastic Cells and Inhibit Osteoclast Formation in Mouse Marrow Cultures," <i>Bone</i> . Vol. 18(1):9-14 (January 1996).	
	CJ	PARFITT, A.M., "Bone-Forming Cells in Clinical Conditions In: Bone Vol. 1 The osteoblast and osteocyte." 351-429 (1996) CRC Press, Boca Raton.	
	CK	PLOTKIN, L.I. et al., "Bisphosphonates Prevent Glucocorticoid-Induced Apoptosis of Osteocytes In Vitro: a Putative Mechanism Influencing Mechanosensing," <i>Bone</i> . 23:S157 (1998).	
amb	CL	PLOTKIN, L.I. et al. "Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin," <i>Journal of Clinical Investigation</i> . Vol. 104(10):1363-1374 (November 1999).	

Examiner Signature	Anne-Marie Baker	Date Considered	3/18/02
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		TECH CENTER 1600/2900		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		09/413,758	
		Filing Date		October 7, 1999	
		First Named Inventor		Man lagas, et al.	
		Group Art Unit		1633	
		Examiner Name			
Sheet	4	of	4	Attorney Docket Number 06572.105003 (ANA1002)	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
amb	DA	POMPEIANO, M. et al. "Onset of apoptotic DNA fragmentation can precede cell elimination by days in the small intestinal villus." <i>Cell Death and Differentiation</i> . Vol. 5:702-709 (1998).	
	DB	REEVE, J. et al. "Anabolic Effect of Low Doses of a Fragment of Human Parathyroid Hormone on the Skeleton in Postmenopausal Osteoporosis." <i>The Lancet</i> . 1035-1038 (May 15, 1976).	
	DC	SAHNI, M. et al. "Bisphosphonates act on rat bone resorption through the mediation of osteoblasts." <i>Journal of Clinical Investigation</i> . Vol. 91:2004-2011 (May 1993).	
	DD	SHORT, B.G. et al. "Automated Double Labeling of Proliferation and Apoptosis in Glutathione S-transferase-positive Hepatocytes in Rats." <i>Journal of Histochemistry & Cytochemistry</i> . Vol. 45(9): 1299-1305 (1997).	
	DE	VERBEIJEN, M.H. et al. "Parathyroid hormone activates mitogen-activated protein kinase via cAMP-mediated pathway independent of Ras." <i>Journal of Biological Chemistry</i> . Vol. 272(6):3423-3429 (February 7, 1997).	
amb	DF ²	WEINSTEIN, R.S. et al., "The Effects of Androgen Deficiency on Murine Bone Remodeling and Bone Mineral Density are Mediated via Cells of the Osteoblastic Lineage," <i>Endocrinology</i> . Vol. 138(9): 4013-4021 (1997).	

Examiner Signature	Anne-Marie Baker	Date Considered	3/18/02
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.